Pioglitazone in optimizing diabetes care and NAFLD: Reappraise the strategy.

Speciality: Diabetology

Description:

A warm welcome to all the medical professionals in this interesting session on Pioglitazone in optimizing diabetes care and NAFLD: Reappraise the strategy
Pioglitazone, a thiazolidinedione, has been reappraised for its role in optimizing diabetes care, particularly for patients with type 2 diabetes mellitus (T2DM). It works by improving insulin sensitivity, thereby enhancing glycemic control and reducing HbA1c levels. Recent studies have reinforced its effectiveness, especially in patients with insulin resistance. Pioglitazone also offers cardiovascular benefits by improving lipid profiles and reducing inflammatory markers, making it a valuable addition to comprehensive diabetes management strategies. However, its use requires careful patient selection and monitoring due to potential side effects, such as weight gain and fluid retention.
Beyond diabetes care, pioglitazone has shown promise in treating non-alcoholic fatty liver disease (NAFLD), a common comorbidity in T2DM patients. NAFLD can progress to non-alcoholic steatohepatitis (NASH) and liver fibrosis, conditions where pioglitazone's insulin-sensitizing properties can be particularly beneficial. Clinical trials indicate that pioglitazone can reduce liver fat content, inflammation, and fibrosis, improving liver function and overall metabolic health. This dual benefit underscores the importance of considering pioglitazone in patients with both T2DM and NAFLD, offering a strategic approach to managing these interconnected conditions.
Therefore, get an overall knowledge of Pioglitazone in opti

See More Webinars @ Hidoc Webinars